CAB44: Generics and drug development
Friday 19 October 2012
- Venue
- Register for this meeting – closed
- Draft Programme
- Background reading
- Hotel Details
- Expenses
Draft programme:
| 09:30 – 09:50 | Registration, refreshments and expenses |
| 09:50 -10:00 | Welcome, introductions, UKCAB updates |
| 10:00 -11:00 | Drug development process and introduction to generics – Rebecca McDowall, HIV i-Base Drug development in relation to PrEP and the PROUD studies – David Dolling, MRC |
| 11:00 – 11.15 | Break |
| 11:15 – 12.30 | Generic HIV drugs – Katy Athersuch, Medical Innovation & Access Policy Adviser, MSF |
| 12:30 – 14:00 | Lunch |
| 14:00 – 15:30 | Conferences feedback by UKCAB members: Silvia Petretti/Angelina Namiba – Women/advocacy and Option B+ Robert James – AIDS2012 – History and Hepatitis Roger Pebody – IAS, BHIVA Chris O’Connor – Washington Snapshot Damian Kelly – WAC Feedback; Living2012, 2015 Pledge |
| 15.30 – 15.35 | Break |
| 15:35 – 16:00 | UKCAB AOB |
| 16.00 | Close |
Background reading:
Generic HIV drugs will widen US treatment net
http://www.nature.com/news/generic-hiv-drugs-will-widen-us-treatment-net-1.11173#/time
The Doha declaration explained
http://www.wto.org/english/tratop_e/dda_e/dohaexplained_e.htm
Robin Hood tax (announced by Francois Hollande at IAS)
http://robinhoodtax.org.uk/latest/big-day-robin-hood-tax
AIDS, drug prices and generic drugs
http://www.avert.org/generic.htm
Financial support
The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.
The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.
We believe that manufacturers who currently develop and market medicines have a responsibility to actively engage with advocacy organisations and that HIV positive people and their advocates should be able to directly question manufacturers about the safety and efficacy of their products and proposals for future research.
For a list of companies that support the UK-CAB please see the “about us” page.